Ipamorelin
Well StudiedGrowth hormone secretagogue
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue through ghrelin receptor (GHS-R1a) activation. It has been studied in endocrinology research for its effects on growth hormone release with reduced impact on cortisol and prolactin levels compared to other GHRPs. Published research has examined its receptor selectivity and pharmacological profile. RaysunPeptide supplies Ipamorelin for qualified research and laboratory applications.
Mechanism of Action
Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Health & Longevity | 200mcg | 1x daily before bed | SubQ |
| Body Composition | 250-300mcg | 2x daily (morning, pre-workout) | SubQ |
| Athletic Performance | 200-250mcg | 2-3x daily | SubQ |
| Sleep & Recovery | 200mcg | 1x daily 30min before bed | SubQ |
| Anti-Aging Protocol | 200-250mcg | 1-2x daily | SubQ |
Research Indications
Growth Hormone
Consistent GH elevation 30-60 minutes post-injection, maintaining natural pulsatile patterns.
Increases insulin-like growth factor-1 through natural GH pathways.
Supports cellular regeneration, collagen synthesis, and tissue repair.
Body Composition
Promotes muscle growth and maintenance through GH-mediated pathways.
Enhances lipolysis and metabolic rate through natural GH elevation.
Recovery
Improved sleep latency and increased slow-wave sleep duration.
Enhanced recovery markers and reduced soreness after training.
Peptide Interactions
Extends GH release for optimal hormone cycles. Popular combination.
Enhances GH receptor upregulation and effectiveness.
Complementary for recovery and tissue repair.
Both stimulate GH; choose one to avoid receptor oversaturation.
Redundant GH pathways may cause receptor desensitization.
Similar mechanism with higher hunger effects; redundant.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Mild hunger increase 20-30 minutes post-injection
- •Slight drowsiness when taken before bed
- •Water retention (mild)
Stop Signs (Seek Medical Attention)
- ⚠Signs of receptor desensitization (reduced response after 3-4 months)
- ⚠Unusual joint pain or swelling
- ⚠Persistent numbness or tingling
Contraindications
- ✕Pregnancy or breastfeeding
- ✕Active cancer or history of cancer
- ✕Severe kidney or liver disease
Quality Checklist
Good Signs ✓
- White, fine crystalline powder with no clumping
- Clear solution after BAC water reconstitution
- Mild hunger response 20-30 minutes post-injection
- Slight drowsiness at bedtime doses
Warning Signs !
- Minimal or no physiological response after 2 weeks (check source)
Bad Signs ✕
- Yellow or discolored powder (suggests degradation)
- Cloudy solution after reconstitution
- No response after extended use
References
Identified ipamorelin as the first GHRP-receptor agonist with selectivity for GH release similar to GHRH. Did not release ACTH or cortisol at doses over 200-fold higher than the ED50 for GH release, distinguishing it from other secretagogues.
View on PubMed →Dose-escalation study in 40 healthy males established terminal half-life of 2 hours, clearance of 0.078 L/h/kg. Ipamorelin induced single-episode GH release peaking at 0.67 hours with dose-proportional pharmacokinetics.
View on PubMed →Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 mcm/day and produced pronounced dose-dependent body weight gain in adult female rats over 15 days.
View on PubMed →In 8-month-old female rats treated for 3 months, ipamorelin combined with glucocorticoid increased maximum tetanic tension and periosteal bone formation rate 4-fold compared to glucocorticoid alone.
View on PubMed →Multicenter, double-blind, placebo-controlled trial in 117 bowel resection patients. Ipamorelin 0.03 mg/kg IV twice daily for up to 7 days was well tolerated but did not significantly improve postoperative ileus outcomes versus placebo.
View on PubMed →FAQs
